Covid19Phase 4AntiCov-220NCT05043324
Prevention and Treatment of Patient Before, During, and After Covid-19 Infection
A Phase 4 study testing AntiCov-220 in people with Covid19, run by Nguyen Thi Trieu, MD at 2 sites in 2 countries.
Trial summary
AntiCov-220 prevents and treats before, during, and after infection with SARS-CoV-2. The composition is fractionally extracted from herbs (Ascorbic Acid, L-Arginine hydrochloride, Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Rutin, Pregnenolone… Read more about this study
- Who is it for?
- Ages 16 to 82 yearsHealthy volunteers can take part
- Conditions the study is for
- Covid19
- What is being tested?
- AntiCov-220
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 82 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 20 Feb 2020to 27 Apr 2022
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 82 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- All patients with underlying medical conditions who have been taking medications for these conditions.
- Patients with AIDS, HIV, HBV, HCV, and patients with co-infections.
- The cancer patients are stable.
- Patients with congenital or acquired immunodeficiency.
Who cannot join
- Unstable cancer patients.
Trial locations and contacts
2 sites in 2 countries.
2 sites in 2 countries
United States1 site
Saigon Biopharma LLC
Wilmington, Delaware, 19801-6601
About this study
AntiCov-220 prevents and treats before, during, and after infection with SARS-CoV-2. The composition is fractionally extracted from herbs (Ascorbic Acid, L-Arginine hydrochloride, Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Rutin, Pregnenolone acetate, Allium sativum, Pyridoxine 5-phosphate, Cyanocobalamin), using flavonoids, isoflavonoids, and pregnenolone in combination with ascorbic acid as the key compounds in preventing and killing SARS-CoV-2; increase antibodies and protect cells; supplementing precursors to help the body strengthen antibodies and reduce the risk of infection; destroy spike protein, toxic protein, help prevent blood clots causing stroke; restore the physiological function of cells after virus infection; helps the body to stabilize the amount of cortisol in the blood as well as stabilize the production of specific antibodies. The composition participates in anti-inflammatory and cell-protecting processes, bringing blood cortisol, B-lymphocytes, Cyfra 21-1, WBC, CRP, fever, dyspnea, and other signs of respiratory tract inflammation to a normal state and normal limit.
Read the detailed description
AntiCov-220 can eliminate COVID-19 and its variants at a very early stage when they have not had enough time to multiply and cause disease. AntiCov-220 contains precursors, flavonoids, and special enzymes responsible for protecting human cell membranes and destroying cell membranes of some viruses, especially, COVID-19 cannot replicate in the presence of AntiCov-220 in the body.
AntiCov-220 contains precursors of cortisol. As the investigators know, cortisol has a cell anti-inflammatory, blood pressure regulation, blood sugar regulation, energy booster, and anti-stress roles. It provides precursors to help direct and balance the amount of cortisol in the body that has been imbalanced before.
AntiCov-220 contains flavonoids and Isoflavonoids that are cytoprotective antioxidants, clinically proven to destroy SARS-CoV-2, HBV, HIV, HCV, viruses, reduce complications after COVID-19 infection, prevent neurological sequelae, stroke, cardiovascular sequelae, respiratory sequelae, ...
The anti-inflammatory, stress-reducing, cell-protective, anti-viral, and immunosuppressive processes are performed by an in vivo method that has proven its effectiveness more than ten years ago. AntiCov-220 is an innovative product that can fight against COVID-19 and its variants in the current epidemic situation.
AntiCov-220 is committed to protecting the community of people infected with HBV, HIV, HCV, and SARS-CoV-2 against the risk of the COVID-19 pandemic and its mutations.
AntiCov-220 is easy to implement, highly effective, and helps reduce public health costs, which is essential in protecting human health.
AntiCov-220 can be used alongside current standard treatment regimens prescribed by the World Health Organization.
- Conditions
- Covid19
- Being tested
- AntiCov-220, AntiCov-220 (placebo)
- Keywords
- AIDS, HIV, HBV, HCV, Stroke, Metabolic dissorder, Stress
- Medical subject headings
- COVID-19, Acquired Immunodeficiency Syndrome, Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AntiCov-220Drug
Also called 1a
The daily maintenance, AntiCov-220 dose is to take 3 times a day, 1 tablet each time.
AntiCov-220 (placebo)Drug
Also called 1b
The daily maintenance, AntiCov-220 (placebo) dose is to take 3 times a day, 1 tablet each time.
| Study group | Role | What they receive |
|---|---|---|
| AntiCov-220 | Experimental | Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 for various therapeutic purposes. Receives: Drug: AntiCov-220 |
| AntiCov-220 (Placebo) | Experimental | Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (placebo) for various therapeutic purposes. Receives: Drug: AntiCov-220 (placebo) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 1)
COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Anticov-220 characterized by the targeting and destruction of COVID-19
- One case of Covid-19 infection with no severe change in a patient with HBeAg (+).
- A case of HIV/AIDS turns back to HIV. Of the 35 follow-up subjects in this group, 20 were vaccinated and 15 were not. (The two cases mentioned above have not been vaccinated).
Measured: - 18 months
Secondary outcomes (1)
Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 2)
COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Anticov-220 characterized by the targeting and destruction of COVID-19
_ No one has been infected with Covid-19. Of the 47 follow-up subjects in this group, 40 were vaccinated and 7 were unvaccinated.
Measured: - 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2021
- Study start20 Feb 2020
- Primary completion20 Apr 2022
- Study completion27 Apr 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Covid19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 82 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nguyen Thi Trieu, MD
- Responsible party
- Sponsor-investigator, Nguyen Thi Trieu, MD, Trieu, Nguyen Thi, M.D.
- Investigators
- Tran Minh Cam Tu, Dr., Principal investigator, Saigon Biopharma Company Limited
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05043324
- Sponsor's protocol ID
- COVID-19 and Immunodeficiency
- Acronym
- AntiCov-220
- Status last verified
- Sep 2025
- First submitted
- 8 Sep 2021
- Last updated
- 11 Sep 2025
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevention and Treatment of Patient Before, During, and After Covid-19 Infection
- ClinicalTrials.gov ID
- NCT05043324
- Acronym / sponsor ID
- AntiCov-220 / COVID-19 and Immunodeficiency
- Conditions
- Covid19
- Keywords
- AIDS, HIV, HBV, HCV, Stroke, Metabolic dissorder, Stress
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 82 participants (actual)
- Lead sponsor
- Nguyen Thi Trieu, MD
- Study start
- 20 Feb 2020 (actual)
- Primary completion
- 20 Apr 2022 (actual)
- Study completion
- 27 Apr 2022 (actual)
- First posted
- 14 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
AntiCov-220 prevents and treats before, during, and after infection with SARS-CoV-2. The composition is fractionally extracted from herbs (Ascorbic Acid, L-Arginine hydrochloride, Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Rutin, Pregnenolone acetate, Allium sativum, Pyridoxine 5-phosphate, Cyanocobalamin), using flavonoids, isoflavonoids, and pregnenolone in combination with ascorbic acid as the key compounds in preventing and killing SARS-CoV-2; increase antibodies and protect cells; supplementing precursors to help the body strengthen antibodies and reduce the risk of infection; destroy spike protein, toxic protein, help prevent blood clots causing stroke; restore the physiological function of cells after virus infection; helps the body to stabilize the amount of cortisol in the blood as well as stabilize the production of specific antibodies. The composition participates in anti-inflammatory and cell-protecting processes, bringing blood cortisol, B-lymphocytes, Cyfra 21-1, WBC, CRP, fever, dyspnea, and other signs of respiratory tract inflammation to a normal state and normal limit.
Detailed description
AntiCov-220 can eliminate COVID-19 and its variants at a very early stage when they have not had enough time to multiply and cause disease. AntiCov-220 contains precursors, flavonoids, and special enzymes responsible for protecting human cell membranes and destroying cell membranes of some viruses, especially, COVID-19 cannot replicate in the presence of AntiCov-220 in the body.
AntiCov-220 contains precursors of cortisol. As the investigators know, cortisol has a cell anti-inflammatory, blood pressure regulation, blood sugar regulation, energy booster, and anti-stress roles. It provides precursors to help direct and balance the amount of cortisol in the body that has been imbalanced before.
AntiCov-220 contains flavonoids and Isoflavonoids that are cytoprotective antioxidants, clinically proven to destroy SARS-CoV-2, HBV, HIV, HCV, viruses, reduce complications after COVID-19 infection, prevent neurological sequelae, stroke, cardiovascular sequelae, respiratory sequelae, ...
The anti-inflammatory, stress-reducing, cell-protective, anti-viral, and immunosuppressive processes are performed by an in vivo method that has proven its effectiveness more than ten years ago. AntiCov-220 is an innovative product that can fight against COVID-19 and its variants in the current epidemic situation.
AntiCov-220 is committed to protecting the community of people infected with HBV, HIV, HCV, and SARS-CoV-2 against the risk of the COVID-19 pandemic and its mutations.
AntiCov-220 is easy to implement, highly effective, and helps reduce public health costs, which is essential in protecting human health.
AntiCov-220 can be used alongside current standard treatment regimens prescribed by the World Health Organization.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| AntiCov-220 | Experimental | Drug: AntiCov-220Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 for various therapeutic purposes. |
| AntiCov-220 (Placebo) | Experimental | Drug: AntiCov-220 (placebo)Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (placebo) for various therapeutic purposes. |
Who may qualify
- Ages
- 16 to 82 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- All patients with underlying medical conditions who have been taking medications for these conditions.
- Patients with AIDS, HIV, HBV, HCV, and patients with co-infections.
- The cancer patients are stable.
- Patients with congenital or acquired immunodeficiency.
Key exclusion criteria (1 listed)
- Unstable cancer patients.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AntiCov-220Also: 1aThe daily maintenance, AntiCov-220 dose is to take 3 times a day, 1 tablet each time. | Drug | AntiCov-220 |
| AntiCov-220 (placebo)Also: 1bThe daily maintenance, AntiCov-220 (placebo) dose is to take 3 times a day, 1 tablet each time. | Drug | AntiCov-220 (Placebo) |
Primary outcome
Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 1)
Time frame: - 18 months
COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Anticov-220 characterized by the targeting and destruction of COVID-19 * One case of Covid-19 infection with no severe change in a patient with HBeAg (+). * A case of HIV/AIDS turns back to HIV. Of the 35 follow-up subjects in this group, 20 were vaccinated and 15 were not. (The two cases mentioned above have not been vaccinated).
1 secondary outcome
Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 2)
Time frame: - 18 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2025.
Related trials for Covid19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tran Minh Cam Tu, Dr. principal investigator
Saigon Biopharma Company Limited
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing AntiCov-220 in people with Covid19, run by Nguyen Thi Trieu, MD at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States, Vietnam. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 1) (time frame: - 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2025.